The initial resistance Group K Diagnostics felt among investors seems to be dissipating.

Though at first the Theranos scandal haunted founder Brianna Wronko in the pitch room — one investor even likening her to Theranos CEO Elizabeth Holmes — the founder and CEO says promising results in clinical trials have turned investors onto backing her startup.

On Monday, the company announced it had secured a $2 million Series A aimed at scaling up production, commercialization and regulatory processes for its technology. The funding was led by “a private holding company that asked not to be named,” Wronko said, but like most investors in the round, the firm had previously backed its seed round.

READ FULL ARTICLE HERE